Axonics Modulation Technologies, which is commercializing a neural implant for overactive bladder and incontinence, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The Irvine, CA-based company was founded in 2012 and booked $0.1 million in sales for the 12 months ended June 30, 2018. It plans to list on the Nasdaq under the symbol AXNX. Axonics Modulation Technologies filed confidentially on August 28, 2018. BofA Merrill Lynch and Morgan Stanley are the joint bookrunners on the deal. No pricing terms were disclosed.
